Sites not expected to fade away even as DCTs continue to grow past COVID-19.
William Chaplin
Advertisement
William Chaplin is a consultant for ZS's R&D excellence team and member of the digital and DCT vertical in clinical development.
Articles by William Chaplin
Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.
Assessing the opportunities, considerations and implications of decentralized trials—and why they’re here to stay
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
3
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
4
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
